After-Hours Movers 9/3: NVLS, ESL, LMNX Higher; ZQK, ULTA, ARST, COO Lower

September 3, 2009 5:24 PM EDT

Quiksilver (NYSE: ZQK) 8.4% LOWER; reports Q3 EPS of $0.03, in-line analyst estimate of $0.03. Revenue for the quarter was $501.4 million, versus the consensus of $480.22 million. Sees Q4 sales down in mid-teen digits. Sese Q4 adj-loss per share in mid-sigle digits.

Novellus (Nasdaq: NVLS) 5.7% HIGHER; CEO, Rick Hill, speaking on a conference call, sees Q3 orders up 40-50% from Q2, up from the previous forecast of 20-50%. Sees a Q3 loss of $0.09 to breakeven, versus the consensus of ($0.06). Sees Q3 sales of $160-$180 million, versus the consensus of $167.83 million. The company had previously been expecting a Q3 loss of $0.15 to breakeven on sales of $150-$180 million. Sees Q3 gross margin of 40%. Sees Q4 EPS of $0.10-$0.20, versus the Street estimate of $0.01, on sales of $200-$230 million, versus the consensus of $181.29 million.

Esterline Corporation (NYSE: ESL) 5% HIGHER; reports Q3 EPS of $1.09 vs. $0.90. Revenues were $361.5 million vs. $367.71 million consensus. Earnings include a tax benefit of approximately $.10 per share. Robert W. Cremin, Esterline CEO, said, "...Esterline posted a very solid quarter, keeping us on pace with our full-year guidance despite continued uncertainty in the commercial airline industry." Esterline's full-year earnings guidance now stands at $3.10 to $3.30 per share, reflecting the third quarter tax benefit. (Consensus is $3.13)

Luminex Corporation (NASDAQ: LMNX) 4.2% HIGHER; has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new cystic fibrosis (CF) test: the xTAG(R) Cystic Fibrosis 39 Kit v2. Click here for the full report.

Ulta Salon, Cosmetics & Fragrance, Inc. (Nasdaq: ULTA) 3.8% LOWER; reports Q2 EPS of $0.10, 5 cents better than the analyst estimate of $0.05. Revenue for the quarter was $273.5 million, versus the consensus of $270.96 million. Q2 comps fell 1.7%. Sees Q3 sales of $270-$278 million, versus the consensus of $273.75 million, with EPS of $0.08-$0.11, versus the Street estimate of $0.09.

ArcSight, Inc. (Nasdaq: ARST) 3.7% LOWER; reports Q1 EPS of $0.09 adjusted, 1 cent better than the analyst estimate of $0.08. Revenue for the quarter was $34.6 million, versus the consensus of $34.13 million. Sees Q2 EPS 10c to 14c versus 12 cents consensus. Sees Q2 revs $38.5M to $42.5M versus $38.4 million consensus.

The Cooper Companies, Inc. (NYSE: COO) 3.2% LOWER; reports Q3 EPS of $0.54, 8 cents worse than the analyst estimate of $0.62. Revenue for the quarter was $285.2 million, versus the consensus of $288.84 million. Cooper Companies sees Q4 EPS of $0.66-$0.68, versus the consensus of $0.60. Cooper Companies sees Q4 sales of $271-$285 million, versus the consensus of $280.3 milion.

To get this report daily, visit http://www.streetinsider.com/entities/After-Hours+Movers.

Related Categories

Special Reports

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?